Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | PREP | P48147 | 2/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.40 |
| ▸ | TMEM97 | Q5BJF2 | 5/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28150248 | 0.79 | NPC1 (0.49) | SMN1; SMN2CYP2C19NPC1RAB9AL3MBTL1 | |
| SCHEMBL2302032 | 0.76 | NPC1 (0.46) | SMN1; SMN2CYP2C19NPC1RAB9AL3MBTL1 | |
| SCHEMBL4866049 | 0.72 | NPC1 (0.49) | SMN1; SMN2CYP2C19NPC1RAB9AL3MBTL1 | |
| SCHEMBL1653568 | 0.71 | XIAP (0.44) | — | |
| SCHEMBL29087342 | 0.68 | SMN1; SMN2 (0.59) | SMN1; SMN2CYP2C19NPC1RAB9APDE4B | |
| SCHEMBL1934002 | 0.68 | NPC1 (0.49) | SMN1; SMN2CYP2C19NPC1RAB9AL3MBTL1 | |
| SCHEMBL2305843 | 0.67 | PREP (0.47) | PREP | |
| SCHEMBL29707055 | 0.67 | NPC1 (0.54) | SMN1; SMN2CYP2C19NPC1RAB9AL3MBTL1 | |
| SCHEMBL8466542 | 0.67 | NPC1 (0.51) | SMN1; SMN2CYP2C19NPC1RAB9AL3MBTL1 | |
| SCHEMBL7405713 | 0.67 | NPC1 (0.48) | SMN1; SMN2CYP2C19NPC1RAB9AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9309252-B2 | Pyrrolopyrimidine compounds as inhibitors of CDK4/6 | NOVARTIS AG (CH) | 2016-04-12 | — | — | US | disclosed |
| EP-2536730-B1 | PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 | NOVARTIS AG (CH) | 2015-07-08 | — | — | EP | disclosed |
| US-20150099737-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 | NOVARTIS AG (CH) | 2015-04-09 | — | — | US | disclosed |
| US-8957074-B2 | Pyrrolopyrimidine compounds as inhibitors of CDK4/6 | NOVARTIS AG (CH) | 2015-02-17 | — | — | US | disclosed |
| US-20130150342-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 | NOVARTIS AG (CH) | 2013-06-13 | — | — | US | disclosed |
| EP-2536730-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 | Novartis AG (CH) | 2012-12-26 | — | — | EP | disclosed |
| WO-2011101409-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 | NOVARTIS AG (CH) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099737-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 | CDK4, CDK6, CCNT1 | SMN1; SMN2 2345/4885CYP2C19 2091/4885NPC1 3953/4885 |
| US-20130150342-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 | CDK4, CDK6, CCNT1 | SMN1; SMN2 2422/4885CYP2C19 2105/4885NPC1 3992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.